

06/28/01
J1051 U.S. PTO

BROWDY AND NEIMARK, P.L.L.C.
ATTORNEYS AT LAW
PATENT AND TRADEMARK CAUSES

SUITE 300
624 NINTH STREET, N W
WASHINGTON, D. C. 20001-5303
TELEPHONE (202)-628-5197

ALVIN BROWDY (1917-1998)
SHERIDAN NEIMARK
ROGER L. BROWDY

ANNE M. KORNBAU
NORMAN J. LATKER
DIANA MICHELLE SOBO*

OF COUNSEL
IVER P. COOPER
JAY M. FINKELSTEIN

TELECOPIER FACSIMILE
(202) 737-3528
(202) 393-1012

E-MAIL
mail@browdyneimark.com

PATENT AGENT
ALLEN C. YUN, PH.D.

*ADMITTED IN FL ONLY
PRACTICE SUPERVISED BY
PRINCIPALS OF THE FIRM

Jc971 U.S. PTO
09/893348
06/28/01

Hon. Assistant Commissioner for Patents
Box Patent Appln
Washington, D.C. 20231

Re: New C.I.P. Patent Application in U.S.
Applicant: Michal EISENBACH-SCHWARTZ et al.
Title: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS...
Atty's Docket: EIS-SCHWARTZ 2A

Sir:

Attached herewith is the above-identified continuation-in-part application for Letters Patent including:

- [] Application Data Sheet
[X] Specification (103 pages), claims (8 pages), abstract (1 page) and sequence listing (57 pages)
[X] 30 Sheets Drawings (Figures 1-25)
[X] FORMAL [] Informal
[X] Sequence Listing with disk and ~~Statements in accordance with 37 C.F.R. § 1.821(f) and 1.821(g)~~ Preliminary Communication
[X] The inventors of this application are:
Michal EISENBACH-SCHWARTZ, of 5 Rupin Street, Rehovot 76353, Israel;
Irun R. COHEN, of 11 Hankin Street, Rehovot 76353, Israel;
Pierre BESERMAN, of Moshav Sitriya 76834, Israel;
Alon MOSONEGO, of Ben-Yosef, Kfar Hanoar Ben-Shemen 73112, Israel; and
Gila MOALEM, of 27 Bosel Street, Rehovot 76405, Israel.
[] Information Disclosure Statement with SB/08A and ___ references
[X] Return Receipt Postcard (in duplicate)

The following statements are applicable:

- [] Applicant hereby requests that this application **not** be published pursuant to 35 U.S.C. §122(a). It is certified on behalf of applicant that the invention disclosed in the application has not been and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing.
[] Applicant claims small entity status. See 37 C.F.R. §1.27.
[X] The benefit under 35 USC §119 is claimed of the filing date of:
Application No. 124500 in Israel on 19 May 1998. A certified copy of said priority document was filed in parent PCT application no. PCT/US98/14715.

098893418-062801

- [] The present application claims the benefit of U.S. Provisional Appln. No. 60/_____, filed ____.
- [X] The present application is a Continuation-in-Part of prior Application No. 09/314,161, filed May 19, 1999, which is a CIP of 09/218,277, filed December 22, 1998, which is a CIP of International Application No. PCT/US98/14715, filed July 21, 1998. Although this application is stated to be a CIP, applicant does not concede that any matter is presented in this application which is not present in the parent.
- [] Amend the specification by inserting before the first line the sentence:
- [] --This is a continuation / division / continuation-in-part of copending parent application No. _____, filed _____--
- [] --The present application claims the benefit of U.S. Provisional Appln. No. 60/_____, filed _____--
- [] --The present application is the national stage under 35 U.S.C. §371 of international application _____ which designated the United States[, which international application was published under PCT Article 21(2) in English].--
- [X] The application is (or will be) assigned to: YEDA RESEARCH AND DEVELOPMENT CO. LTD., whose address is Weizmann Institute of Science, P.O. Box 95, Rehovot, Israel 76 100.
- [X] Certain documents were previously cited or submitted to the Patent and Trademark Office in the following prior application 09/314,161, which is relied upon under 35 USC §120. Applicants identify these documents by attaching hereto form PTO-1449s listing these documents, and request that they be considered and made of record in accordance with 37 CFR §1.98(d). Per Section 1.98(d), copies of these documents need not be filed in this application.
- [] Incorporation By Reference. The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied herewith, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
- [X] In accordance with 37 CFR 1.53(a) and (b), it is respectfully requested that a serial number and filing date be assigned to this application as of the date of receipt of the present papers. In accordance with the present procedures of the U.S. Patent and Trademark Office, an executed Declaration and the filing fee for the present application will be filed in due course.
- [X] **No authorization is given for charging the filing fee at the present time. However, at such time that the declaration is filed, but not before, you are authorized to charge whatever excess fees are necessary (including the filing fee and any extension of time fees then due) to Deposit Account 02-4035, if any such fees due are not fully covered by check filed at that time.**
- [X] The attorneys of record for this application and the address will be those of **Customer No. 001444**; i.e., Sheridan Neimark, Reg. No. 20,520; Roger L. Browdy, Reg. No. 25,618; Anne M. Kornbau, Reg. No. 25,884; Norman J. Latker, Reg. 19,963; Iver P. Cooper, Reg. No. 28,005; Jay M. Finkelstein, Reg. No. 21,082; and *Allen C. Yun, Reg. No. 37,971 (*Patent Agent). Please send all correspondence with respect to this case to:

BROWDY AND NEIMARK, P.L.L.C.
624 Ninth Street, N.W.
Washington, D.C. 20001

Please direct all telephone calls to Browdy and Neimark at (202) 628-5197.

[X] The Commissioner is hereby authorized to credit any overpayment of fees accompanying this paper to Deposit Account No. 02-4035.

Respectfully submitted,
BROWDY AND NEIMARK, P.L.L.C.

By:

Roger L. Browdy
Registration No. 25,618

RLB:edg

F:\Y\YEDA\eis-schwartz2a\Pto\newCIP53transmittal2.doc

1. The first part of the report discusses the importance of maintaining accurate records of all transactions, including sales, purchases, and expenses. It emphasizes the need for consistency and thoroughness in record-keeping to ensure the reliability of financial data.

2. The second part of the report provides a detailed analysis of the company's financial performance over the past year. It includes a comparison of actual results with budgeted figures and identifies areas where the company has exceeded or fallen short of expectations.

3. The third part of the report outlines the company's financial goals for the upcoming year. It includes a discussion of the strategies that will be implemented to achieve these goals, such as increasing sales, reducing costs, and improving operational efficiency.

4. The fourth part of the report discusses the company's financial risks and the measures that will be taken to mitigate them. It includes a discussion of the company's credit policy, its approach to managing debt, and its plans for maintaining adequate liquidity.

5. The fifth part of the report provides a summary of the company's financial position and a conclusion. It includes a discussion of the company's overall financial health and its outlook for the future.